Dietmar Neubacher - Concepedia

Author

Dietmar Neubacher

Boehringer Ingelheim (Germany)

Also Known As

D. Neubacher, DIETMAR NEUBACHER, Dietmar Neubacher

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Boehringer Ingelheim (United States)Harvard University Joslin Diabetes Center University of Toronto

About

Dietmar Neubacher is an author at Boehringer Ingelheim (Germany) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	488
2	Health Sciences	3	3	441
3	Engineering	2	2	87
4	Computer Engineering	1	1	72
5	Data Science	1	1	15

Dietmar Neubacher

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials Julio Rosenstock, Jan Marquard, Lori M. Laffel, Diabetes Care	2018	339
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials Charles B. Hicks, Pedro Cahn, David A. Cooper, The Lancet Durable EfficacyTreatment-experienced Hiv-1-infected PatientsHiv/aids CounsellingStrategic InterventionHealth Sciences	2006	322
Effect of linagliptin monotherapy on glycaemic control and markers of <i>β</i> ‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial Stefano Del Prato, Anthony Barnett, Holger Huisman, Diabetes Obesity and Metabolism	2010	296
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial Lori M. Laffel, Thomas Danne, Georgeanna J. Klingensmith, The Lancet Diabetes & Endocrinology Metabolic SyndromeDiabetes ManagementYoung PeopleCardiovascular DiseaseInsulin Management	2023	98
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events Julio Rosenstock, Nikolaus Marx, Dietmar Neubacher, Cardiovascular Diabetology	2015	81
Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial Pedro Cahn, Jorge Villacian, Adriano Lazzarin, Clinical Infectious Diseases	2006	81
A conceptual modeling framework for discrete event simulation using hierarchical control structures Nikolaus Furian, Michael O’Sullivan, Cameron Walker, Simulation Modelling Practice and Theory Hierarchical Control StructuresEngineeringSimulationPrevious Cm FrameworksDiscrete-event Simulation	2015	72
Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1) Susanne Famulla, Thomas R. Pieber, Jens Eilbracht, Diabetes Technology & Therapeutics	2016	52
Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis Bernard Zinman, Bo Åhrén, Dietmar Neubacher, Canadian Journal of Diabetes Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseInsulin ManagementDiabetes	2015	32
Long-Term Efficacy and Safety of Tipranavir Boosted With Ritonavir in HIV-1-Infected Patients Failing Multiple Protease Inhibitor Regimens Martin Markowitz, Leonard N. Slater, Robert A. Schwartz, JAIDS Journal of Acquired Immune Deficiency Syndromes	2007	22

Page 1